Literature DB >> 21908709

Crystal structure of FAS thioesterase domain with polyunsaturated fatty acyl adduct and inhibition by dihomo-gamma-linolenic acid.

Wei Zhang1, Bornali Chakravarty, Fei Zheng, Ziwei Gu, Hongmei Wu, Jianqiang Mao, Salih J Wakil, Florante A Quiocho.   

Abstract

Human fatty acid synthase (hFAS) is a homodimeric multidomain enzyme that catalyzes a series of reactions leading to the de novo biosynthesis of long-chain fatty acids, mainly palmitate. The carboxy-terminal thioesterase (TE) domain determines the length of the fatty acyl chain and its ultimate release by hydrolysis. Because of the upregulation of hFAS in a variety of cancers, it is a target for antiproliferative agent development. Dietary long-chain polyunsaturated fatty acids (PUFAs) have been known to confer beneficial effects on many diseases and health conditions, including cancers, inflammations, diabetes, and heart diseases, but the precise molecular mechanisms involved have not been elucidated. We report the 1.48 Å crystal structure of the hFAS TE domain covalently modified and inactivated by methyl γ-linolenylfluorophosphonate. Whereas the structure confirmed the phosphorylation by the phosphonate head group of the active site serine, it also unexpectedly revealed the binding of the 18-carbon polyunsaturated γ-linolenyl tail in a long groove-tunnel site, which itself is formed mainly by the emergence of an α helix (the "helix flap"). We then found inhibition of the TE domain activity by the PUFA dihomo-γ-linolenic acid; γ- and α-linolenic acids, two popular dietary PUFAs, were less effective. Dihomo-γ-linolenic acid also inhibited fatty acid biosynthesis in 3T3-L1 preadipocytes and selective human breast cancer cell lines, including SKBR3 and MDAMB231. In addition to revealing a novel mechanism for the molecular recognition of a polyunsaturated fatty acyl chain, our results offer a new framework for developing potent FAS inhibitors as therapeutics against cancers and other diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21908709      PMCID: PMC3179057          DOI: 10.1073/pnas.1112334108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  The CCP4 suite: programs for protein crystallography.

Authors: 
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-09-01

2.  Trifluoromethyl ketones and methyl fluorophosphonates as inhibitors of group IV and VI phospholipases A(2): structure-function studies with vesicle, micelle, and membrane assays.

Authors:  F Ghomashchi; R Loo; J Balsinde; F Bartoli; R Apitz-Castro; J D Clark; E A Dennis; M H Gelb
Journal:  Biochim Biophys Acta       Date:  1999-08-20

3.  Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain.

Authors:  Bornali Chakravarty; Ziwei Gu; Subrahmanyam S Chirala; Salih J Wakil; Florante A Quiocho
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-26       Impact factor: 11.205

4.  Repression of cellular anaplerosis as the hypothesized mechanism of gamma-linolenic acid-induced toxicity to tumor cells.

Authors:  J O Nwankwo
Journal:  Med Hypotheses       Date:  2001-05       Impact factor: 1.538

5.  Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells.

Authors:  Binqiu Liu; Yingqiang Wang; Kerry L Fillgrove; Vernon E Anderson
Journal:  Cancer Chemother Pharmacol       Date:  2002-01-09       Impact factor: 3.333

6.  Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase.

Authors:  X Wang; W Tian
Journal:  Biochem Biophys Res Commun       Date:  2001-11-16       Impact factor: 3.575

7.  Suppression of fatty acid synthase by dietary polyunsaturated fatty acids is mediated by fat itself, not by peroxidative mechanism.

Authors:  Hyekyeong Kim; Sungwon Choi; Hae-Jeung Lee; Joo-Hee Lee; Haymie Choi
Journal:  J Biochem Mol Biol       Date:  2003-05-31

8.  Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.

Authors:  Javier A Menendez; Santiago Ropero; Inderjit Mehmi; Ella Atlas; Ramon Colomer; Ruth Lupu
Journal:  Int J Oncol       Date:  2004-06       Impact factor: 5.650

9.  Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity.

Authors:  Steven J Kridel; Fumiko Axelrod; Natasha Rozenkrantz; Jeffrey W Smith
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Synthesis and antitumor activity of an inhibitor of fatty acid synthase.

Authors:  F P Kuhajda; E S Pizer; J N Li; N S Mani; G L Frehywot; C A Townsend
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  9 in total

1.  Probing the modularity of megasynthases by rational engineering of a fatty acid synthase Type I.

Authors:  Alexander Rittner; Karthik S Paithankar; David Jan Drexler; Aaron Himmler; Martin Grininger
Journal:  Protein Sci       Date:  2018-12-20       Impact factor: 6.725

Review 2.  Lipids and prostate cancer.

Authors:  Janel Suburu; Yong Q Chen
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-04-05       Impact factor: 3.072

Review 3.  Architecture of the polyketide synthase module: surprises from electron cryo-microscopy.

Authors:  Janet L Smith; Georgios Skiniotis; David H Sherman
Journal:  Curr Opin Struct Biol       Date:  2015-03-16       Impact factor: 6.809

4.  Thioesterase enzyme families: Functions, structures, and mechanisms.

Authors:  Benjamin T Caswell; Caio C de Carvalho; Hung Nguyen; Monikrishna Roy; Tin Nguyen; David C Cantu
Journal:  Protein Sci       Date:  2022-01-04       Impact factor: 6.725

5.  Crystal structure of the human fatty acid synthase enoyl-acyl carrier protein-reductase domain complexed with triclosan reveals allosteric protein-protein interface inhibition.

Authors:  Katherine H Sippel; Nand K Vyas; Wei Zhang; Banumathi Sankaran; Florante A Quiocho
Journal:  J Biol Chem       Date:  2014-10-09       Impact factor: 5.157

6.  Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.

Authors:  Anup Aggarwal; Maloy K Parai; Nishant Shetty; Deeann Wallis; Lisa Woolhiser; Courtney Hastings; Noton K Dutta; Stacy Galaviz; Ramesh C Dhakal; Rupesh Shrestha; Shoko Wakabayashi; Chris Walpole; David Matthews; David Floyd; Paul Scullion; Jennifer Riley; Ola Epemolu; Suzanne Norval; Thomas Snavely; Gregory T Robertson; Eric J Rubin; Thomas R Ioerger; Frik A Sirgel; Ruben van der Merwe; Paul D van Helden; Peter Keller; Erik C Böttger; Petros C Karakousis; Anne J Lenaerts; James C Sacchettini
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

7.  Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.

Authors:  Valerie E Fako; Xi Wu; Beth Pflug; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  J Med Chem       Date:  2014-12-29       Impact factor: 7.446

8.  Keys to Lipid Selection in Fatty Acid Amide Hydrolase Catalysis: Structural Flexibility, Gating Residues and Multiple Binding Pockets.

Authors:  Giulia Palermo; Inga Bauer; Pablo Campomanes; Andrea Cavalli; Andrea Armirotti; Stefania Girotto; Ursula Rothlisberger; Marco De Vivo
Journal:  PLoS Comput Biol       Date:  2015-06-25       Impact factor: 4.475

9.  Type I fatty acid synthase trapped in the octanoyl-bound state.

Authors:  Alexander Rittner; Karthik S Paithankar; Aaron Himmler; Martin Grininger
Journal:  Protein Sci       Date:  2020-02       Impact factor: 6.725

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.